AU2006235364A1 - RNAi therapeutic for respiratory virus infection - Google Patents

Info

Publication number

AU2006235364A1

AU2006235364A1 AU2006235364A AU2006235364A AU2006235364A1 AU 2006235364 A1 AU2006235364 A1 AU 2006235364A1 AU 2006235364 A AU2006235364 A AU 2006235364A AU 2006235364 A AU2006235364 A AU 2006235364A AU 2006235364 A1 AU2006235364 A1 AU 2006235364A1

Authority

AU

Australia

Prior art keywords

virus

sirna

nucleic acid

rnai

viral

Prior art date

2005-04-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 230000009368 gene silencing by RNA Effects 0.000 title claims description 164
• 230000009385 viral infection Effects 0.000 title claims description 50
• 230000000241 respiratory effect Effects 0.000 title claims description 47
• 108091030071 RNAI Proteins 0.000 title claims description 36
• 230000001225 therapeutic effect Effects 0.000 title claims description 29
• 108020004459 Small interfering RNA Proteins 0.000 claims description 758
• 239000004055 small Interfering RNA Substances 0.000 claims description 563
• 241000700605 Viruses Species 0.000 claims description 327
• 210000004027 cell Anatomy 0.000 claims description 177
• 125000003729 nucleotide group Chemical group 0.000 claims description 161
• 150000007523 nucleic acids Chemical group 0.000 claims description 156
• 239000002773 nucleotide Substances 0.000 claims description 152
• 230000003612 virological effect Effects 0.000 claims description 150
• 108090000623 proteins and genes Proteins 0.000 claims description 148
• 241000712461 unidentified influenza virus Species 0.000 claims description 146
• 238000004519 manufacturing process Methods 0.000 claims description 93
• 206010022000 influenza Diseases 0.000 claims description 91
• 238000000034 method Methods 0.000 claims description 90
• 239000000203 mixture Substances 0.000 claims description 90
• 230000001939 inductive effect Effects 0.000 claims description 86
• 239000003795 chemical substances by application Substances 0.000 claims description 84
• 102000039446 nucleic acids Human genes 0.000 claims description 84
• 108020004707 nucleic acids Proteins 0.000 claims description 84
• 108010067390 Viral Proteins Proteins 0.000 claims description 81
• 230000005764 inhibitory process Effects 0.000 claims description 77
• 230000000295 complement effect Effects 0.000 claims description 75
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 70
• 230000014509 gene expression Effects 0.000 claims description 70
• 102000004169 proteins and genes Human genes 0.000 claims description 64
• 108010061100 Nucleoproteins Proteins 0.000 claims description 51
• 150000001875 compounds Chemical class 0.000 claims description 37
• 239000012634 fragment Substances 0.000 claims description 35
• 239000000523 sample Substances 0.000 claims description 31
• 241000725643 Respiratory syncytial virus Species 0.000 claims description 28
• 241000342334 Human metapneumovirus Species 0.000 claims description 24
• 241000709661 Enterovirus Species 0.000 claims description 23
• 241000282414 Homo sapiens Species 0.000 claims description 22
• 108091027967 Small hairpin RNA Proteins 0.000 claims description 22
• 241000894007 species Species 0.000 claims description 22
• 239000003814 drug Substances 0.000 claims description 20
• 230000002401 inhibitory effect Effects 0.000 claims description 19
• 208000036142 Viral infection Diseases 0.000 claims description 18
• 241001559187 Human rubulavirus 2 Species 0.000 claims description 17
• 108700005077 Viral Genes Proteins 0.000 claims description 17
• 210000002345 respiratory system Anatomy 0.000 claims description 17
• 241000712041 Human parainfluenza virus 4a Species 0.000 claims description 16
• 241000712036 Human parainfluenza virus 4b Species 0.000 claims description 16
• 241000726041 Human respirovirus 1 Species 0.000 claims description 15
• 241000712003 Human respirovirus 3 Species 0.000 claims description 15
• 230000037396 body weight Effects 0.000 claims description 15
• 229920006317 cationic polymer Polymers 0.000 claims description 14
• 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 13
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 12
• 241000711920 Human orthopneumovirus Species 0.000 claims description 11
• 108700010900 influenza virus proteins Proteins 0.000 claims description 10
• 210000004962 mammalian cell Anatomy 0.000 claims description 8
• 210000000805 cytoplasm Anatomy 0.000 claims description 6
• 238000009007 Diagnostic Kit Methods 0.000 claims description 4
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 4
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 4
• 241000699670 Mus sp. Species 0.000 description 153
• 208000015181 infectious disease Diseases 0.000 description 139
• 210000004072 lung Anatomy 0.000 description 133
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 129
• 108020004999 messenger RNA Proteins 0.000 description 107
• 108020000999 Viral RNA Proteins 0.000 description 93
• 230000000692 anti-sense effect Effects 0.000 description 74
• 238000011282 treatment Methods 0.000 description 65
• 238000003556 assay Methods 0.000 description 61
• 230000000694 effects Effects 0.000 description 60
• 241000699666 Mus <mouse, genus> Species 0.000 description 57
• 239000013598 vector Substances 0.000 description 51
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 48
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 48
• 239000005090 green fluorescent protein Substances 0.000 description 48
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 46
• 239000002953 phosphate buffered saline Substances 0.000 description 45
• 230000030279 gene silencing Effects 0.000 description 39
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 38
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 38
• 238000012384 transportation and delivery Methods 0.000 description 37
• 238000013518 transcription Methods 0.000 description 36
• 230000035897 transcription Effects 0.000 description 36
• 102000011931 Nucleoproteins Human genes 0.000 description 35
• 108020004414 DNA Proteins 0.000 description 34
• 238000002474 experimental method Methods 0.000 description 34
• 238000009472 formulation Methods 0.000 description 34
• 108090001074 Nucleocapsid Proteins Proteins 0.000 description 33
• 239000000463 material Substances 0.000 description 32
• 230000010076 replication Effects 0.000 description 29
• 208000037797 influenza A Diseases 0.000 description 28
• 239000002585 base Substances 0.000 description 26
• 241001493065 dsRNA viruses Species 0.000 description 24
• 239000013612 plasmid Substances 0.000 description 24
• 238000009825 accumulation Methods 0.000 description 23
• 241000282898 Sus scrofa Species 0.000 description 22
• 238000003753 real-time PCR Methods 0.000 description 22
• 210000003501 vero cell Anatomy 0.000 description 22
• 241001465754 Metazoa Species 0.000 description 21
• 230000035931 haemagglutination Effects 0.000 description 21
• 206010012310 Dengue fever Diseases 0.000 description 20
• 230000015572 biosynthetic process Effects 0.000 description 20
• -1 cRNA Proteins 0.000 description 20
• 238000006731 degradation reaction Methods 0.000 description 20
• 238000003786 synthesis reaction Methods 0.000 description 20
• 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 19
• 101710102873 Polymerase basic protein 2 Proteins 0.000 description 19
• 238000004458 analytical method Methods 0.000 description 19
• 230000015556 catabolic process Effects 0.000 description 19
• 108010048032 cyclophilin B Proteins 0.000 description 19
• 108010044156 peptidyl-prolyl cis-trans isomerase b Proteins 0.000 description 19
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
• 239000010410 layer Substances 0.000 description 18
• 230000009467 reduction Effects 0.000 description 18
• 238000001727 in vivo Methods 0.000 description 17
• 230000002829 reductive effect Effects 0.000 description 17
• 239000006228 supernatant Substances 0.000 description 17
• 241000287828 Gallus gallus Species 0.000 description 16
• 238000001990 intravenous administration Methods 0.000 description 16
• 238000001890 transfection Methods 0.000 description 16
• 230000029812 viral genome replication Effects 0.000 description 16
• 108091034117 Oligonucleotide Proteins 0.000 description 15
• 238000009396 hybridization Methods 0.000 description 15
• 230000001629 suppression Effects 0.000 description 15
• 239000012228 culture supernatant Substances 0.000 description 14
• 230000006870 function Effects 0.000 description 14
• 238000010839 reverse transcription Methods 0.000 description 14
• 239000000243 solution Substances 0.000 description 14
• 238000002560 therapeutic procedure Methods 0.000 description 14
• 208000009714 Severe Dengue Diseases 0.000 description 13
• 239000000872 buffer Substances 0.000 description 13
• 201000002950 dengue hemorrhagic fever Diseases 0.000 description 13
• 230000000069 prophylactic effect Effects 0.000 description 13
• 101710154606 Hemagglutinin Proteins 0.000 description 12
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 12
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 12
• 101710176177 Protein A56 Proteins 0.000 description 12
• 239000000185 hemagglutinin Substances 0.000 description 12
• 238000000338 in vitro Methods 0.000 description 12
• 230000001965 increasing effect Effects 0.000 description 12
• 238000002360 preparation method Methods 0.000 description 12
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
• 241000713666 Lentivirus Species 0.000 description 11
• 108091081021 Sense strand Proteins 0.000 description 11
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 11
• 229910052799 carbon Inorganic materials 0.000 description 11
• 238000004520 electroporation Methods 0.000 description 11
• 230000001404 mediated effect Effects 0.000 description 11
• 230000035772 mutation Effects 0.000 description 11
• 230000002441 reversible effect Effects 0.000 description 11
• 230000008685 targeting Effects 0.000 description 11
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
• 238000011156 evaluation Methods 0.000 description 10
• 238000004128 high performance liquid chromatography Methods 0.000 description 10
• 210000001519 tissue Anatomy 0.000 description 10
• 210000002845 virion Anatomy 0.000 description 10
• 239000005089 Luciferase Substances 0.000 description 9
• 108060004795 Methyltransferase Proteins 0.000 description 9
• 101710081079 Minor spike protein H Proteins 0.000 description 9
• 230000027455 binding Effects 0.000 description 9
• 238000004113 cell culture Methods 0.000 description 9
• 201000010099 disease Diseases 0.000 description 9
• 231100000673 dose–response relationship Toxicity 0.000 description 9
• 235000013601 eggs Nutrition 0.000 description 9
• 229920000642 polymer Polymers 0.000 description 9
• 229920001184 polypeptide Polymers 0.000 description 9
• 102000004196 processed proteins & peptides Human genes 0.000 description 9
• 108090000765 processed proteins & peptides Proteins 0.000 description 9
• 125000002652 ribonucleotide group Chemical group 0.000 description 9
• 239000011780 sodium chloride Substances 0.000 description 9
• 238000012360 testing method Methods 0.000 description 9
• 230000014616 translation Effects 0.000 description 9
• 108060001084 Luciferase Proteins 0.000 description 8
• 238000002123 RNA extraction Methods 0.000 description 8
• 108700019146 Transgenes Proteins 0.000 description 8
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 8
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
• 230000003321 amplification Effects 0.000 description 8
• 208000025729 dengue disease Diseases 0.000 description 8
• 238000010790 dilution Methods 0.000 description 8
• 239000012895 dilution Substances 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• 239000012530 fluid Substances 0.000 description 8
• 239000008103 glucose Substances 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 238000003199 nucleic acid amplification method Methods 0.000 description 8
• 239000002245 particle Substances 0.000 description 8
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 7
• 208000001490 Dengue Diseases 0.000 description 7
• 150000001413 amino acids Chemical class 0.000 description 7
• 210000000234 capsid Anatomy 0.000 description 7
• 238000003776 cleavage reaction Methods 0.000 description 7
• 108091036078 conserved sequence Proteins 0.000 description 7
• 230000000875 corresponding effect Effects 0.000 description 7
• 230000007423 decrease Effects 0.000 description 7
• 238000001514 detection method Methods 0.000 description 7
• 108010048367 enhanced green fluorescent protein Proteins 0.000 description 7
• 210000003743 erythrocyte Anatomy 0.000 description 7
• 229940026289 infasurf Drugs 0.000 description 7
• 230000007246 mechanism Effects 0.000 description 7
• 230000001717 pathogenic effect Effects 0.000 description 7
• 239000008194 pharmaceutical composition Substances 0.000 description 7
• 239000000902 placebo Substances 0.000 description 7
• 229940068196 placebo Drugs 0.000 description 7
• 238000012545 processing Methods 0.000 description 7
• 238000001243 protein synthesis Methods 0.000 description 7
• 230000002685 pulmonary effect Effects 0.000 description 7
• 238000006467 substitution reaction Methods 0.000 description 7
• 229960005486 vaccine Drugs 0.000 description 7
• 239000003981 vehicle Substances 0.000 description 7
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 6
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 241000712431 Influenza A virus Species 0.000 description 6
• 101150118742 NP gene Proteins 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 241000702670 Rotavirus Species 0.000 description 6
• 241000710886 West Nile virus Species 0.000 description 6
• 230000000996 additive effect Effects 0.000 description 6
• 230000003247 decreasing effect Effects 0.000 description 6
• 229940124447 delivery agent Drugs 0.000 description 6
• 238000009826 distribution Methods 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 6
• 230000001771 impaired effect Effects 0.000 description 6
• 239000004615 ingredient Substances 0.000 description 6
• 230000037361 pathway Effects 0.000 description 6
• 230000007017 scission Effects 0.000 description 6
• 239000002904 solvent Substances 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 238000011725 BALB/c mouse Methods 0.000 description 5
• 241000725619 Dengue virus Species 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 5
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 5
• 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 5
• 108700011259 MicroRNAs Proteins 0.000 description 5
• 230000004570 RNA-binding Effects 0.000 description 5
• 108091028664 Ribonucleotide Proteins 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 239000003242 anti bacterial agent Substances 0.000 description 5
• 230000000840 anti-viral effect Effects 0.000 description 5
• 239000012736 aqueous medium Substances 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 230000001413 cellular effect Effects 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 239000002299 complementary DNA Substances 0.000 description 5
• 238000013461 design Methods 0.000 description 5
• 238000011534 incubation Methods 0.000 description 5
• 231100000518 lethal Toxicity 0.000 description 5
• 230000001665 lethal effect Effects 0.000 description 5
• 230000000670 limiting effect Effects 0.000 description 5
• 239000002609 medium Substances 0.000 description 5
• 201000009240 nasopharyngitis Diseases 0.000 description 5
• 239000002777 nucleoside Substances 0.000 description 5
• 238000003305 oral gavage Methods 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• 230000002265 prevention Effects 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 238000011321 prophylaxis Methods 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 5
• 239000002336 ribonucleotide Substances 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 230000006490 viral transcription Effects 0.000 description 5
• 238000005406 washing Methods 0.000 description 5
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• 244000309467 Human Coronavirus Species 0.000 description 4
• 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 4
• 102000007999 Nuclear Proteins Human genes 0.000 description 4
• 108010089610 Nuclear Proteins Proteins 0.000 description 4
• 229910019142 PO4 Inorganic materials 0.000 description 4
• 238000000692 Student's t-test Methods 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• 239000000443 aerosol Substances 0.000 description 4
• 208000006673 asthma Diseases 0.000 description 4
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 210000002919 epithelial cell Anatomy 0.000 description 4
• 238000000684 flow cytometry Methods 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• 239000012678 infectious agent Substances 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 230000008520 organization Effects 0.000 description 4
• 238000004806 packaging method and process Methods 0.000 description 4
• 235000021317 phosphate Nutrition 0.000 description 4
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 229910001415 sodium ion Inorganic materials 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 238000012546 transfer Methods 0.000 description 4
• YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 4
• 229950004616 tribromoethanol Drugs 0.000 description 4
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 4
• 229940045145 uridine Drugs 0.000 description 4
• 230000017613 viral reproduction Effects 0.000 description 4
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 241000283690 Bos taurus Species 0.000 description 3
• 206010006448 Bronchiolitis Diseases 0.000 description 3
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
• 108090000565 Capsid Proteins Proteins 0.000 description 3
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
• 102100023321 Ceruloplasmin Human genes 0.000 description 3
• 241000711573 Coronaviridae Species 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 102000053602 DNA Human genes 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• 241000710198 Foot-and-mouth disease virus Species 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 3
• 206010061598 Immunodeficiency Diseases 0.000 description 3
• 208000002979 Influenza in Birds Diseases 0.000 description 3
• 241001500351 Influenzavirus A Species 0.000 description 3
• 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 3
• 101710163270 Nuclease Proteins 0.000 description 3
• 230000007022 RNA scission Effects 0.000 description 3
• 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 3
• 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 3
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
• 108010052090 Renilla Luciferases Proteins 0.000 description 3
• 206010061494 Rhinovirus infection Diseases 0.000 description 3
• 102000004389 Ribonucleoproteins Human genes 0.000 description 3
• 108010081734 Ribonucleoproteins Proteins 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 229960005305 adenosine Drugs 0.000 description 3
• 229940121375 antifungal agent Drugs 0.000 description 3
• 239000003429 antifungal agent Substances 0.000 description 3
• 206010064097 avian influenza Diseases 0.000 description 3
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 238000011734 black swiss mouse Methods 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 230000004087 circulation Effects 0.000 description 3
• 239000008121 dextrose Substances 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 239000012537 formulation buffer Substances 0.000 description 3
• 238000001502 gel electrophoresis Methods 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
• 230000010354 integration Effects 0.000 description 3
• 230000010468 interferon response Effects 0.000 description 3
• 238000010253 intravenous injection Methods 0.000 description 3
• 231100000636 lethal dose Toxicity 0.000 description 3
• 208000030500 lower respiratory tract disease Diseases 0.000 description 3
• 239000000178 monomer Substances 0.000 description 3
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
• 108010058731 nopaline synthase Proteins 0.000 description 3
• 210000001331 nose Anatomy 0.000 description 3
• 125000003835 nucleoside group Chemical group 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 238000001543 one-way ANOVA Methods 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 102000054765 polymorphisms of proteins Human genes 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 238000003757 reverse transcription PCR Methods 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 2
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
• 102100027324 2-hydroxyacyl-CoA lyase 1 Human genes 0.000 description 2
• DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 description 2
• AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 2
• HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 2
• 108010000700 Acetolactate synthase Proteins 0.000 description 2
• 229930024421 Adenine Natural products 0.000 description 2
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• 208000037874 Asthma exacerbation Diseases 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 108091032955 Bacterial small RNA Proteins 0.000 description 2
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
• 238000011740 C57BL/6 mouse Methods 0.000 description 2
• 101710132601 Capsid protein Proteins 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
• NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
• 108010066133 D-octopine dehydrogenase Proteins 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 102100023387 Endoribonuclease Dicer Human genes 0.000 description 2
• 241000991587 Enterovirus C Species 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 101001009252 Homo sapiens 2-hydroxyacyl-CoA lyase 1 Proteins 0.000 description 2
• 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• 241000430519 Human rhinovirus sp. Species 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 102100034349 Integrase Human genes 0.000 description 2
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
• 239000012097 Lipofectamine 2000 Substances 0.000 description 2
• 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 241001115401 Marburgvirus Species 0.000 description 2
• 241000351643 Metapneumovirus Species 0.000 description 2
• 239000012124 Opti-MEM Substances 0.000 description 2
• 241000711504 Paramyxoviridae Species 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 108010076039 Polyproteins Proteins 0.000 description 2
• 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 208000035415 Reinfection Diseases 0.000 description 2
• 208000037656 Respiratory Sounds Diseases 0.000 description 2
• 206010057190 Respiratory tract infections Diseases 0.000 description 2
• 102000004142 Trypsin Human genes 0.000 description 2
• 108090000631 Trypsin Proteins 0.000 description 2
• 241000711975 Vesicular stomatitis virus Species 0.000 description 2
• 206010058874 Viraemia Diseases 0.000 description 2
• 108010065667 Viral Matrix Proteins Proteins 0.000 description 2
• 206010047924 Wheezing Diseases 0.000 description 2
• 241000710772 Yellow fever virus Species 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 229960000643 adenine Drugs 0.000 description 2
• 230000001464 adherent effect Effects 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 210000005058 airway cell Anatomy 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 238000000137 annealing Methods 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 125000002091 cationic group Chemical group 0.000 description 2
• 230000005754 cellular signaling Effects 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 230000001010 compromised effect Effects 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 231100000517 death Toxicity 0.000 description 2
• 201000009892 dengue shock syndrome Diseases 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 238000010586 diagram Methods 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 206010014599 encephalitis Diseases 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 238000012226 gene silencing method Methods 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 229940029575 guanosine Drugs 0.000 description 2
• 125000005843 halogen group Chemical group 0.000 description 2
• 238000003306 harvesting Methods 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 239000002955 immunomodulating agent Substances 0.000 description 2
• 229940121354 immunomodulator Drugs 0.000 description 2
• 229960001438 immunostimulant agent Drugs 0.000 description 2
• 239000003022 immunostimulating agent Substances 0.000 description 2
• 230000003308 immunostimulating effect Effects 0.000 description 2
• 239000003701 inert diluent Substances 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 238000011081 inoculation Methods 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 230000002452 interceptive effect Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
• 210000005265 lung cell Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 210000001161 mammalian embryo Anatomy 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• 239000002679 microRNA Substances 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 239000007922 nasal spray Substances 0.000 description 2
• 231100000956 nontoxicity Toxicity 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 150000003833 nucleoside derivatives Chemical class 0.000 description 2
• PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 230000007918 pathogenicity Effects 0.000 description 2
• 230000002974 pharmacogenomic effect Effects 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 230000005180 public health Effects 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 208000023504 respiratory system disease Diseases 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 230000001743 silencing effect Effects 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 238000012385 systemic delivery Methods 0.000 description 2
• 229940061367 tamiflu Drugs 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 239000012096 transfection reagent Substances 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 239000012588 trypsin Substances 0.000 description 2
• HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 229940051021 yellow-fever virus Drugs 0.000 description 2
• MXYRZDAGKTVQIL-IOSLPCCCSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-2-methyloxolane-3,4-diol Chemical compound C1=NC2=C(N)N=CN=C2N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O MXYRZDAGKTVQIL-IOSLPCCCSA-N 0.000 description 1
• RIFDKYBNWNPCQK-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 description 1
• ASAADZNSXOCOCZ-MXSWDONDSA-N (2s,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolane-2-carboxylic acid Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H]1O ASAADZNSXOCOCZ-MXSWDONDSA-N 0.000 description 1
• GZEFTKHSACGIBG-UGKPPGOTSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-propyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1=CC(=O)NC(=O)N1[C@]1(CCC)O[C@H](CO)[C@@H](O)[C@H]1O GZEFTKHSACGIBG-UGKPPGOTSA-N 0.000 description 1
• RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 1
• QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 1
• PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
• IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 description 1
• CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
• IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
• ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 1
• JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
• RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 1
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
• XXSIICQLPUAUDF-TURQNECASA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XXSIICQLPUAUDF-TURQNECASA-N 0.000 description 1
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
• FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
• ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
• KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
• UEHOMUNTZPIBIL-UUOKFMHZSA-N 6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7h-purin-8-one Chemical compound O=C1NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UEHOMUNTZPIBIL-UUOKFMHZSA-N 0.000 description 1
• ASUCSHXLTWZYBA-UMMCILCDSA-N 8-Bromoguanosine Chemical compound C1=2NC(N)=NC(=O)C=2N=C(Br)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ASUCSHXLTWZYBA-UMMCILCDSA-N 0.000 description 1
• 102000055025 Adenosine deaminases Human genes 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 241000272525 Anas platyrhynchos Species 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 241000710189 Aphthovirus Species 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000031504 Asymptomatic Infections Diseases 0.000 description 1
• 241000711404 Avian avulavirus 1 Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000283153 Cetacea Species 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 241000204955 Colorado tick fever virus Species 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 206010010264 Condition aggravated Diseases 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000709687 Coxsackievirus Species 0.000 description 1
• 241000709675 Coxsackievirus B3 Species 0.000 description 1
• 206010011416 Croup infectious Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical class OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
• 230000004543 DNA replication Effects 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
• 241000255925 Diptera Species 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 241001115402 Ebolavirus Species 0.000 description 1
• 206010014612 Encephalitis viral Diseases 0.000 description 1
• 241000710188 Encephalomyocarditis virus Species 0.000 description 1
• 101710091045 Envelope protein Proteins 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 241000710781 Flaviviridae Species 0.000 description 1
• 241000710831 Flavivirus Species 0.000 description 1
• 208000005577 Gastroenteritis Diseases 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 241000190708 Guanarito mammarenavirus Species 0.000 description 1
• 241000150562 Hantaan orthohantavirus Species 0.000 description 1
• 241000893570 Hendra henipavirus Species 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 241000724709 Hepatitis delta virus Species 0.000 description 1
• 241000709715 Hepatovirus Species 0.000 description 1
• 241000709721 Hepatovirus A Species 0.000 description 1
• 108091027305 Heteroduplex Proteins 0.000 description 1
• 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
• 241001479210 Human astrovirus Species 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 101900155339 Human metapneumovirus Nucleoprotein Proteins 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 241000712890 Junin mammarenavirus Species 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 206010023927 Lassa fever Diseases 0.000 description 1
• OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
• 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
• 241000712898 Machupo mammarenavirus Species 0.000 description 1
• 241000712079 Measles morbillivirus Species 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• YGULWPYYGQCFMP-CEAXSRTFSA-N Metoprolol tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 YGULWPYYGQCFMP-CEAXSRTFSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 241000711513 Mononegavirales Species 0.000 description 1
• 241000711386 Mumps virus Species 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• 101150076514 NS gene Proteins 0.000 description 1
• JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000008457 Neurologic Manifestations Diseases 0.000 description 1
• 241000369774 Norwalk-like virus Species 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 101710141454 Nucleoprotein Proteins 0.000 description 1
• 206010068319 Oropharyngeal pain Diseases 0.000 description 1
• 241000712464 Orthomyxoviridae Species 0.000 description 1
• 241000702244 Orthoreovirus Species 0.000 description 1
• 239000007990 PIPES buffer Substances 0.000 description 1
• 241000711502 Paramyxovirinae Species 0.000 description 1
• 241000873939 Parechovirus A Species 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 201000007100 Pharyngitis Diseases 0.000 description 1
• IAJOBQBIJHVGMQ-UHFFFAOYSA-N Phosphinothricin Natural products CP(O)(=O)CCC(N)C(O)=O IAJOBQBIJHVGMQ-UHFFFAOYSA-N 0.000 description 1
• 108010089430 Phosphoproteins Proteins 0.000 description 1
• 102000007982 Phosphoproteins Human genes 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 235000014676 Phragmites communis Nutrition 0.000 description 1
• 241000709664 Picornaviridae Species 0.000 description 1
• 241000711904 Pneumoviridae Species 0.000 description 1
• 241000711902 Pneumovirus Species 0.000 description 1
• 208000000474 Poliomyelitis Diseases 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 229940096437 Protein S Drugs 0.000 description 1
• 101710136297 Protein VP2 Proteins 0.000 description 1
• 101710188315 Protein X Proteins 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
• 230000006819 RNA synthesis Effects 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 241000702247 Reoviridae Species 0.000 description 1
• 241000702263 Reovirus sp. Species 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 241001113283 Respirovirus Species 0.000 description 1
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
• 241000713124 Rift Valley fever virus Species 0.000 description 1
• 241000710799 Rubella virus Species 0.000 description 1
• 241001533467 Rubulavirus Species 0.000 description 1
• CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
• 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
• 241000192617 Sabia mammarenavirus Species 0.000 description 1
• 241001135555 Sandfly fever Sicilian virus Species 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 241000150288 Sin Nombre orthohantavirus Species 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 101710198474 Spike protein Proteins 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 101710172711 Structural protein Proteins 0.000 description 1
• 229920006328 Styrofoam Polymers 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
• 101710137500 T7 RNA polymerase Proteins 0.000 description 1
• 238000011053 TCID50 method Methods 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
• 201000006449 West Nile encephalitis Diseases 0.000 description 1
• 206010057293 West Nile viral infection Diseases 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 208000012873 acute gastroenteritis Diseases 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 238000003915 air pollution Methods 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000003342 alkenyl group Chemical group 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• 239000013566 allergen Substances 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
• 229960003805 amantadine Drugs 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 238000003287 bathing Methods 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• 102000005936 beta-Galactosidase Human genes 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 210000000621 bronchi Anatomy 0.000 description 1
• 210000003123 bronchiole Anatomy 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
• 244000309466 calf Species 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 239000008004 cell lysis buffer Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000010479 cellular ifn response Effects 0.000 description 1
• 230000004640 cellular pathway Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000010835 comparative analysis Methods 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 229940125773 compound 10 Drugs 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 210000000795 conjunctiva Anatomy 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 239000007771 core particle Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 238000011262 co‐therapy Methods 0.000 description 1
• 201000010549 croup Diseases 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000000593 degrading effect Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 229960001271 desloratadine Drugs 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000000378 dietary effect Effects 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000000312 effect on influenza Effects 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 230000001159 endocytotic effect Effects 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 244000309457 enveloped RNA virus Species 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 230000003631 expected effect Effects 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000003633 gene expression assay Methods 0.000 description 1
• 238000010363 gene targeting Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 238000003205 genotyping method Methods 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• IAJOBQBIJHVGMQ-BYPYZUCNSA-N glufosinate-P Chemical compound CP(O)(=O)CC[C@H](N)C(O)=O IAJOBQBIJHVGMQ-BYPYZUCNSA-N 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 208000005252 hepatitis A Diseases 0.000 description 1
• 201000010284 hepatitis E Diseases 0.000 description 1
• 150000002402 hexoses Chemical class 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000010039 intracellular degradation Effects 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 210000001985 kidney epithelial cell Anatomy 0.000 description 1
• 230000006651 lactation Effects 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
• 229960005287 lincomycin Drugs 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 229960003088 loratadine Drugs 0.000 description 1
• JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
• 102100039604 mRNA guanylyltransferase Human genes 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 210000004779 membrane envelope Anatomy 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
• 229940012189 methyl orange Drugs 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 238000002493 microarray Methods 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 229940051866 mouthwash Drugs 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 230000000869 mutational effect Effects 0.000 description 1
• 210000002850 nasal mucosa Anatomy 0.000 description 1
• 229940097496 nasal spray Drugs 0.000 description 1
• 239000006218 nasal suppository Substances 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
• 229960003752 oseltamivir Drugs 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 239000013610 patient sample Substances 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 150000004713 phosphodiesters Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 108091005981 phosphorylated proteins Proteins 0.000 description 1
• 238000000053 physical method Methods 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 239000002984 plastic foam Substances 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 230000004088 pulmonary circulation Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 239000002213 purine nucleotide Substances 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 239000002719 pyrimidine nucleotide Substances 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 230000017610 release of virus from host Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 210000001533 respiratory mucosa Anatomy 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• 229920002477 rna polymer Polymers 0.000 description 1
• RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 230000003584 silencer Effects 0.000 description 1
• 238000001374 small-angle light scattering Methods 0.000 description 1
• 238000002791 soaking Methods 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 208000003265 stomatitis Diseases 0.000 description 1
• 239000008261 styrofoam Substances 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000002636 symptomatic treatment Methods 0.000 description 1
• 230000009044 synergistic interaction Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 239000013638 trimer Substances 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 238000009777 vacuum freeze-drying Methods 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 208000005925 vesicular stomatitis Diseases 0.000 description 1
• 201000002498 viral encephalitis Diseases 0.000 description 1
• 230000006648 viral gene expression Effects 0.000 description 1
• 244000052613 viral pathogen Species 0.000 description 1
• 230000007485 viral shedding Effects 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
• 229960001028 zanamivir Drugs 0.000 description 1
• 206010048282 zoonosis Diseases 0.000 description 1